Financing ·
Rapport raises $412M via $172.5M convertible notes due 2032 and $245.7M equity offering
RAPPRapport Therapeutics, Inc.
Rapport Therapeutics closed a combined capital raise of approximately $412 million on October 30, 2026. The company issued $172.5 million in aggregate principal amount of 2.25% convertible senior notes due 2032, generating net proceeds of roughly $166.8 million. Concurrently, it completed an underwritten public offering and private placement (PIPE) raising approximately $245.7 million in net equity proceeds. The total capital is intended to fund ongoing clinical trials for RAP-219, research and development, and general corporate purposes through the end of 2029. Rapport Therapeutics operates as a biopharmaceutical company focused on developing treatments for neurological disorders.